1. De Vita, V. T., & Chu, E. (2003). Drug development. Principles and Practice in Oncology. Philadelphia, Lippincott, 354.
2. Weiss, R. B., Sarosy, G., Clagett-Carr, K., Russo, M., & Leyland-Jones, B. (1986). Anthracycline analogs: The past, present, and future. Cancer Chemotherapy Pharmacology, 18, 185–197.
3. Verweij, J., & Kees Nooter (2002). Principles of Chemoterapy. Oxford, 564.
4. Hortobagyi, G. N. (1997). Anthracyclines in the treatment of cancer: An overview. Drugs, 54(Suppl 4), 1–7.
5. Zunino, F., & Capranico, G. (1992). DNA topisomerasas II as the primary target of antitumoral anthracyclines. Anticancer Drug Designs, 5, 307–317.